Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral GC4711 vs IV GC4419 or GC4711 in Healthy Volunteers
NCT03099824Phase 1Completed
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rucosopasem manganese in non-small cell lung cancer (NSCLC) and pancreatic cancer (PC) (7 arms), sponsored by Galera Therapeutics, Inc. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities up to 13 days. Started Oct 2018; status: completed.
02
Drugs
rucosopasem manganese
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03099824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099824.